A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Bartlett, David B ^a   Connelly, Margery A ^b   AbouAssi, Hiba ^a   Bateman, Lori A ^c   Tune, K Noelle ^c   Huebner, Janet L ^a   Kraus, Virginia B ^a   Winegar, Deborah A ^b   Otvos, James D ^b   Kraus, William E ^a   Huffman, Kim M ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LIPOSCIENCE INC   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Biomarker; Glycosylation; Inflammation; Metabolic syndrome; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLYCA PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN;

ABDOMINAL OBESITY; ADULT; AGE; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DENSITY; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENDER; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MALE; MUSCLE DENSITY; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; RHEUMATOID ARTHRITIS; WAIST CIRCUMFERENCE; AGED; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; GLYCOSYLATION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PATHOLOGY; PHYSIOLOGY; RISK FACTOR;

ACUTE-PHASE PROTEINS; ADIPOSITY; ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOMARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOSYLATION; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 84962800207     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-0982-5     Document Type: Article

References (41)

1. Dessein PH, Joffe BI, Stanwix AE. Editorial: should we evaluate insulin sensitivity in rheumatoid arthritis? Semin Arthritis Rheum. 2005;35(1):5-7.
2. AbouAssi H, Tune KN, Gilmore B, Bateman LA, McDaniel G, Muehlbauer M, et al. Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis. J Rheumatol. 2014;41(10):1974-9. doi: 10.3899/jrheum.140224.
3. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52(2):402-11. doi: 10.1002/art.20853.
4. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005;17(3):286-92.
5. van Breukelen-van der Stoep DF, Klop B, van Zeben D, Hazes JM, Castro CM. Cardiovascular risk in rheumatoid arthritis: how to lower the risk? Atherosclerosis. 2013;231(1):163-72. doi: 10.1016/j.atherosclerosis.2013.09.006.
6. Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol. 2014;33:115-21.
7. Otvos JD, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin Chem. 2015;61(5):714-23. doi: 10.1373/clinchem.2014.232918.
8. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;3(5):e001221. doi: 10.1161/JAHA.114.001221.
9. Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;23(115):305635.
10. Lawler P, Akinkuolie AO, Buring JE, Ridker PM, Glynn RJ, Mora S. A novel biomarker of circulating glycoproteins and cardiovascular and all-cause mortality among 39,521 initially healthy adults. J Am Coll Cardiol. 2015;65(10S):A1358.
11. Connelly MA, Gruppen EG, Wolak-Dinsmore J, Matyus SP, Riphagen IJ, Shalaurova I, et al. GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clin Chim Acta. 2015;452:10-7. doi: 10.1016/j.cca.2015.11.001.
12. Gruppen EG, Riphagen IJ, Connelly MA, Otvos JD, Bakker SJ, Dullaart RP. GlycA, a pro-inflammatory glycoprotein biomarker, and incident cardiovascular disease: relationship with C-reactive protein and renal function. PloS One. 2015;10(9):e0139057. doi: 10.1371/journal.pone.0139057.
13. Ormseth MJ, Chung CP, Oeser AM, Connelly MA, Sokka T, Raggi P, et al. Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Res Ther. 2015;17:117. doi: 10.1186/s13075-015-0646-x.
14. Chung CP, Ormseth MJ, Connelly MA, Oeser A, Solus JF, Otvos JD, et al. GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus. Lupus. 2016;25(3):296-300. doi: 10.1177/0961203315617842.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
16. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26(4):847-70. doi: 10.1016/j.cll.2006.07.006.
17. Lowry R. VassarStats: website for statistical computation. Vassar College. 1998-2015. http://vassarstats.net. Accessed November 2015.
18. Chandrashekara S, Sachin S. Measures in rheumatoid arthritis: are we measuring too many parameters. Int J Rheum Dis. 2012;15(3):239-48. doi: 10.1111/j.1756-185X.2012.01754.x.
19. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12.
20. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52(6):847-53. doi: 10.1136/gut.52.6.847.
21. Arnold JN, Saldova R, Hamid UMA, Rudd PM. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. PROTEOMICS. 2008;8(16):3284-93. doi: 10.1002/pmic.200800163.
22. Marino K, Bones J, Kattla JJ, Rudd PM. A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol. 2010;6(10):713-23.
23. Gornik O, Lauc G. Glycosylation of serum proteins in inflammatory diseases. Dis Markers. 2008;25(4-5):267-78. doi: 10.1155/2008/493289.
24. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987;84(20):7251-5.
25. Badolato R, Oppenheim JJ. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum. 1996;26(2):526-38. doi: 10.1016/S0049-0172(96)80041-2.
26. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman H-J, Law SKA, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409(6817):198-201.
27. Houssiau FA, Devogelaer J-P, Damme JV, Deuxchaisnes CND, Snick JV. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(6):784-8. doi: 10.1002/art.1780310614.
28. Park S-Y, Lee S-H, Kawasaki N, Itoh S, Kang K, Hee Ryu S, et al. α1-3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers. Int J Cancer. 2012;130(10):2366-76. doi: 10.1002/ijc.26288.
29. Thompson S, Dargan E, Griffiths ID, Kelly CA, Turner GA. The glycosylation of haptoglobin in rheumatoid arthritis. Clin Chim Acta. 1993;220(1):107-14. doi: 10.1016/0009-8981(93)90011-R.
30. Saldova R, Wormald MR, Dwek RA, Rudd PM. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers. 2008;25(4-5):219-32.
31. Park HJ, Oh M-K, Kim N-H, Cho M-L, Kim I-S. Identification of a specific haptoglobin C-terminal fragment in arthritic synovial fluid and its effect on interleukin-6 expression. Immunology. 2013;140(1):133-41. doi: 10.1111/imm.12125.
32. Theilgaard-Mönch K, Jacobsen LC, Nielsen MJ, Rasmussen T, Udby L, Gharib M, et al. Haptoglobin is synthesized during granulocyte differentiation, stored in specific granules, and released by neutrophils in response to activation. Blood. 2006;108(1):353-61. doi: 10.1182/blood-2005-09-3890.
33. Kim I-S, Lee I-H, Lee J-H, Lee S-Y. Induction of haptoglobin by all-trans retinoic acid in THP-1 human monocytic cell line. Biochem Biophys Res Commun. 2001;284(3):738-42. doi: 10.1006/bbrc.2001.5041.
34. Dullaart RP, Gruppen EG, Connelly MA, Otvos JD, Lefrandt JD. GlycA, a biomarker of inflammatory glycoproteins, is more closely related to the leptin/adiponectin ratio than to glucose tolerance status. Clin Biochem. 2015;48(12):811-14. doi: 10.1016/j.clinbiochem.2015.05.001.
35. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015;64(1):131-45. doi: 10.1016/j.metabol.2014.10.016.
36. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009;52(11):2345-9. doi: 10.1007/s00125-009-1508-3.
37. Volin MV, Koch AE. Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interferon Cytokine Res. 2011;31(10):745-51. doi: 10.1089/jir.2011.0050.
38. Yang Z, Cao J, Yu C, Yang Q, Zhang Y, Han L. Caspase-1 mediated interleukin-18 activation in neutrophils promotes the activity of rheumatoid arthritis in a NLRP3 inflammasome independent manner. Joint Bone Spine. 2016;5(15):00270-5.
39. Skurk T, Kolb H, Müller-Scholze S, Röhrig K, Hauner H, Herder C. The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol. 2005;152(6):863-8. doi: 10.1530/eje.1.01897.
40. Bruun JM, Stallknecht B, Helge JW, Richelsen B. Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol. 2007;157(4):465-71. doi: 10.1530/eje-07-0206.
41. Troseid M, Seljeflot I, Arnesen H. The role of interleukin-18 in the metabolic syndrome. Cardiovasc Diabetol. 2010;9:11. doi: 10.1186/1475-2840-9-11.